Efficacy and safety of once daily insulin IDeg/Asp switching from basal insulin in inadequately controlled Japanese patients with type 2 diabetes: A 4-week, randomized, open-label, treat-to-target trial

Trial Profile

Efficacy and safety of once daily insulin IDeg/Asp switching from basal insulin in inadequately controlled Japanese patients with type 2 diabetes: A 4-week, randomized, open-label, treat-to-target trial

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2018 New trial record
    • 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top